Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Britain backs slew of 'long COVID' research studies

Published 18/07/2021, 00:07
Updated 18/07/2021, 00:10
© Reuters. FILE PHOTO: Scientists work at a laboratory where they sequence the novel coronavirus genomes at COVID-19 Genomics UK, on the Wellcome Sanger Institute's 55-acre campus south of Cambridge, Britain March 12, 2021. Picture taken March 12, 2021.  REUTERS/Dyl

LONDON (Reuters) - Britain is backing 15 new studies into the treatment and diagnosis of "long COVID", a condition that can include dozens of symptoms and last for months after an initial bout of infection with COVID-19.

The projects, which will have nearly 20 million pounds ($27.54 million) of government funding, will focus on better understanding the condition, identifying effective treatments and the best ways to care for those suffering from it.

People with long COVID can have symptoms ranging from fatigue and brain fog to breathlessness and organ damage, experts have said.

"This package of research will provide much needed hope to people with long-term health problems after COVID-19," said Nick Lemoine, chair of the National Institute for Health Research's long COVID funding committee.

One study, at University College London, will recruit more than 4,500 people with long COVID to test the effectiveness of existing drugs as treatments over three months to see the impact on symptoms, mental health and the ability to return to work.

It will also look at whether MRI scans can be used to diagnose organ damage.

Another study at Cardiff University will look at whether the condition is caused by overactive or impaired immune responses, while research at Leeds, Oxford and Glasgow will examine the best care regime, the causes of breathlessness and the impact of obesity among people with long COVID, respectively.

The government has previously announced 100 million pounds for services to support those with long COVID, with 80 assessment services open in England so far.

© Reuters. FILE PHOTO: Scientists work at a laboratory where they sequence the novel coronavirus genomes at COVID-19 Genomics UK, on the Wellcome Sanger Institute's 55-acre campus south of Cambridge, Britain March 12, 2021. Picture taken March 12, 2021.  REUTERS/Dylan Martinez/File Photo

"This new research is absolutely essential to improve diagnosis and treatments and will be life-changing for those who are battling long-term symptoms of the virus," health minister Sajid Javid said.

($1 = 0.7261 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.